Health Care [ 4/12 ] | Biotechnology [ 20/74 ]
NASDAQ | Common Stock
Sutro Biopharma, Inc. operates as a oncology company.
The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+.
Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer.
The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers.
Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC.
The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 12, 25 | -0.91 Increased by +4.21% | -0.92 Increased by +1.09% |
| Mar 24, 25 | -0.63 Decreased by -221.77% | -0.95 Increased by +33.70% |
| Nov 11, 24 | -0.50 Increased by +38.49% | -0.73 Increased by +31.75% |
| Aug 13, 24 | -0.59 Increased by +7.81% | -0.79 Increased by +25.32% |
| May 13, 24 | -0.95 Decreased by -11.76% | -0.92 Decreased by -3.26% |
| Mar 25, 24 | 0.52 Increased by +176.47% | -0.82 Increased by +163.41% |
| Nov 13, 23 | -0.81 Decreased by -118.92% | -0.74 Decreased by -9.46% |
| Aug 10, 23 | -0.64 Decreased by -16.36% | -0.73 Increased by +12.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 17.40 M Increased by +33.76% | -75.97 M Decreased by -30.50% | Decreased by -436.62% Increased by +2.43% |
| Dec 31, 24 | 14.81 M Decreased by -86.98% | -72.44 M Decreased by -333.20% | Decreased by -489.18% Decreased by -1.89 K% |
| Sep 30, 24 | 8.52 M Decreased by -49.66% | -48.79 M Increased by +1.01% | Decreased by -572.62% Decreased by -96.64% |
| Jun 30, 24 | 25.71 M Increased by +146.89% | -48.02 M Decreased by -24.64% | Decreased by -186.80% Increased by +49.51% |
| Mar 31, 24 | 13.01 M Increased by +2.64% | -58.21 M Decreased by -16.31% | Decreased by -447.52% Decreased by -13.32% |
| Dec 31, 23 | 113.72 M Increased by +1.22 K% | 31.07 M Increased by +183.75% | Increased by +27.32% Increased by +106.36% |
| Sep 30, 23 | 16.92 M Decreased by -32.70% | -49.28 M Decreased by -177.41% | Decreased by -291.21% Decreased by -312.19% |
| Jun 30, 23 | 10.41 M Decreased by -62.94% | -38.52 M Decreased by -48.10% | Decreased by -370.00% Decreased by -299.64% |